307 related articles for article (PubMed ID: 33378571)
1. A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients.
Ringer M; Azmy V; Kaman K; Tang D; Cheung H; Azar MM; Price C; Malinis M
Transpl Infect Dis; 2021 Apr; 23(2):e13556. PubMed ID: 33378571
[TBL] [Abstract][Full Text] [Related]
2. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.
Azmy V; Kaman K; Tang D; Zhao H; Dela Cruz C; Topal JE; Malinis M; Price CC
J Clin Immunol; 2021 May; 41(4):738-747. PubMed ID: 33459964
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study.
Pereira MR; Aversa MM; Farr MA; Miko BA; Aaron JG; Mohan S; Cohen DJ; Husain SA; Ratner LE; Arcasoy S; Uriel N; Zheng EX; Fox AN; Tsapepas DS; Emond JC; Verna EC
Am J Transplant; 2020 Nov; 20(11):3198-3205. PubMed ID: 32946668
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network.
Hadi YB; Naqvi SFZ; Kupec JT; Sofka S; Sarwari A
Transplantation; 2021 Jun; 105(6):1365-1371. PubMed ID: 33988341
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab therapy in 5 solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2.
Morillas JA; Marco Canosa F; Srinivas P; Asadi T; Calabrese C; Rajendram P; Budev M; Poggio ED; Narayanan Menon KV; Gastman B; Koval C
Am J Transplant; 2020 Nov; 20(11):3191-3197. PubMed ID: 32476261
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
8. Repurposed Tocilizumab in Patients with Severe COVID-19.
Tian J; Zhang M; Jin M; Zhang F; Chu Q; Wang X; Chen C; Yue H; Zhang L; Du R; Zhao D; Zeng Z; Zhao Y; Liu K; Wang M; Hu K; Miao X; Zhang H
J Immunol; 2021 Feb; 206(3):599-606. PubMed ID: 33298617
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.
Fernández-Ruiz M; López-Medrano F; Pérez-Jacoiste Asín MA; Maestro de la Calle G; Bueno H; Caro-Teller JM; Catalán M; de la Calle C; García-García R; Gómez C; Laguna-Goya R; Lizasoáin M; Martínez-López J; Origüen J; Pablos JL; Ripoll M; San Juan R; Trujillo H; Lumbreras C; Aguado JM
J Med Virol; 2021 Feb; 93(2):831-842. PubMed ID: 32672860
[TBL] [Abstract][Full Text] [Related]
10. Use of tocilizumab in kidney transplant recipients with COVID-19.
Pérez-Sáez MJ; Blasco M; Redondo-Pachón D; Ventura-Aguiar P; Bada-Bosch T; Pérez-Flores I; Melilli E; Sánchez-Cámara LA; López-Oliva MO; Canal C; Shabaka A; Garra-Moncau N; Martín-Moreno PL; López V; Hernández-Gallego R; Siverio O; Galeano C; Espí-Reig J; Cabezas CJ; Rodrigo MT; Llinàs-Mallol L; Fernández-Reyes MJ; Cruzado-Vega L; Pérez-Tamajón L; Santana-Estupiñán R; Ruiz-Fuentes MC; Tabernero G; Zárraga S; Ruiz JC; Gutiérrez-Dalmau A; Mazuecos A; Sánchez-Álvarez E; Crespo M; Pascual J;
Am J Transplant; 2020 Nov; 20(11):3182-3190. PubMed ID: 32654422
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK
J Clin Pharm Ther; 2021 Apr; 46(2):440-446. PubMed ID: 33098139
[TBL] [Abstract][Full Text] [Related]
13. Early use of tocilizumab in solid organ transplant recipients with COVID-19: A retrospective cohort study in Saudi Arabia.
Yamani AH; Alraddadi BM; Almaghrabi RS; Amer AA; Mehdawi FS; Al-Hamzi MA; Aldajani MS; Alattas MS; Elsaed Ramadan AM; Wali GY; Alshukairi AN; Al Mutair A
Immun Inflamm Dis; 2022 Mar; 10(3):e587. PubMed ID: 35029324
[TBL] [Abstract][Full Text] [Related]
14. Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.
Janssen MTHF; Ramiro S; Landewé RBM; Magro-Checa C; Mostard RLM
Ann Rheum Dis; 2021 Oct; 80(10):1362-1363. PubMed ID: 33958327
[No Abstract] [Full Text] [Related]
15. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.
Soin AS; Kumar K; Choudhary NS; Sharma P; Mehta Y; Kataria S; Govil D; Deswal V; Chaudhry D; Singh PK; Gupta A; Agarwal V; Kumar S; Sangle SA; Chawla R; Narreddy S; Pandit R; Mishra V; Goel M; Ramanan AV
Lancet Respir Med; 2021 May; 9(5):511-521. PubMed ID: 33676589
[TBL] [Abstract][Full Text] [Related]
16. Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2.
Petrak RM; Skorodin NC; Van Hise NW; Fliegelman RM; Pinsky J; Didwania V; Anderson M; Diaz M; Shah K; Chundi VV; Hines DW; Harting BP; Sidwha K; Yu B; Brune P; Owaisi A; Beezhold D; Kent J; Vais D; Han A; Gowda N; Sahgal N; Silverman J; Stake J; Nepomuceno J; Heddurshetti R
Clin Transl Sci; 2021 Nov; 14(6):2146-2151. PubMed ID: 32918792
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
de la Calle C; López-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sánchez-Fernández M; Fernández-Ruiz M; Pérez-Jacoiste Asín MA; Caro-Teller JM; García-García R; Catalán M; Martínez-López J; Sevillano Á; Origüen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gómez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM
Int J Infect Dis; 2021 Apr; 105():319-325. PubMed ID: 33592340
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
19. Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab.
Mella A; Mingozzi S; Gallo E; Lavacca A; Rossetti M; Clari R; Randone O; Maffei S; Salomone M; Imperiale D; Biancone L
Transpl Infect Dis; 2020 Dec; 22(6):e13348. PubMed ID: 32500936
[TBL] [Abstract][Full Text] [Related]
20. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
